• Molecular NameCelecoxib
  • Synonymcelecoxib; Celocoxib
  • Weight381.378
  • Drugbank_IDDB00482
  • ACS_NO169590-42-5
  • Show 3D model
  • LogP (experiment)4.157
  • LogP (predicted, AB/LogP v2.0)3.92
  • pka11.1
  • LogD (pH=7, predicted)3.92
  • Solubility (experiment)0.0033 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.62
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors2
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA85.84
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis.
  • Absorption_valueN/A
  • Absorption (description)Celecoxib is well and rapidly absorbed
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding97.0
  • Volume of distribution (VD)6.12 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (mainly CYP2C9). Metabolised in the liver to primary alcohol, the corresponding carboxylic acid (the primary metabolite) and its glucuronide conjugate.
  • Half life11.2 h
  • ExcretionThe drug is widely distributed throughout the body. It is eliminated predominantly by hepatic metabolism (>97%), with approx. 57% of the dose excreted in faeces and 27% urine.
  • Urinary Excretion<3
  • Clerance6.60 ml/min/kg
  • ToxicityAcute overdose: coma, hypertension, acute renal failure and respiratory depression.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A